BioCryst Pharmaceuticals, Inc. (BCRX)

7.59 +0.02 (+0.26%) USD  |  NASDAQ  |  Dec 15, 16:00
7.49 -0.10 (-1.32%) After-Hours: 05:04
More

BioCryst Pharmaceuticals Research and Development Expense (Quarterly): 44.27M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for BCRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Astria Therapeutics, Inc. 24.15M
Johnson & Johnson 3.693B
Viatris, Inc. 244.80M
KalVista Pharmaceuticals, Inc. 11.99M
Novavax, Inc. 98.17M